Nucleic Acid Extraction Patents: Who Leads, Where the Gaps Are 2026
Nucleic acid extraction automation patents: mapping the filers, the claim density and the open ground
Filing peaked in 2021 at 243 records and has fallen 41% by 2024 (243 → 143), the last year the dataset treats as complete. Filings rose from 160 in 2017 to a peak of 243 in 2021, then declined to 143 by 2024 — a 41% drop over that three-year span. Treat 2025 and 2026 figures as incomplete rather than as evidence the field is winding down.
- 1FOUNDATION MEDICINE INC6.3%
- 2HANDYLAB INC4.4%
- 3QIAGEN GMBH2.6%
- 4QUEST DIAGNOSTICS INVESTMENTS INC2.3%
- 5CALIFORNIA INST OF TECH2.1%
See the full nucleic acid extraction automation analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on this landscape
Who are the leading patent holders in automated nucleic acid extraction?
The ranking covers 100 assignees counted in records, with the leader holding 183 records and fifth place holding 61. The top 5 combined account for 17.7% of all 2,912 records in scope, and the top 10 combined reach 26.4%, which means most of the field’s activity sits outside the ranked leaders in a long tail of smaller filers. This spread matters for freedom-to-operate work: no single company controls enough of the space to be the sole gatekeeper.
Is patent filing in nucleic acid extraction automation still growing?
Filings peaked at 243 in 2021 and fell to 143 by 2024, a 41% decline over that three-year span, which is the most recent period the dataset treats as complete. Counts for 2025 and 2026 are still low but should not be read as a continued slowdown, since publication typically lags actual filing by around 18 months. The honest read is that the field passed its filing peak in 2021 and has since settled to a lower but still active rate.
Which technology areas carry the densest patent claims?
C12Q, covering enzyme and DNA measuring and testing methods, appears in 60.7% of the 2,912 records and is the single densest class. C12N genetic-engineering claims follow at 29.3% and general material analysis under G01N at 27.8%, while physical lab-apparatus claims under B01L sit lower at 21.3%. This pattern suggests the more contested claim space is in assay chemistry and workflow logic rather than in cassette or instrument hardware design.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Nucleic Acid Extraction Automation covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.